Adaptimmune Therapeutics PLC (ADAP)
0.9847
-0.05
(-4.40%)
USD |
NASDAQ |
Apr 17, 14:31
Adaptimmune Therapeutics SG&A Expense (Quarterly): 16.88M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 16.88M |
September 30, 2023 | 16.16M |
June 30, 2023 | 20.07M |
March 31, 2023 | 18.69M |
December 31, 2022 | 12.92M |
September 30, 2022 | 16.82M |
June 30, 2022 | 14.55M |
March 31, 2022 | 16.80M |
December 31, 2021 | 14.78M |
September 30, 2021 | 15.17M |
June 30, 2021 | 13.54M |
March 31, 2021 | 13.82M |
December 31, 2020 | 13.24M |
September 30, 2020 | 13.00M |
June 30, 2020 | 10.30M |
March 31, 2020 | 9.261M |
December 31, 2019 | 10.73M |
September 30, 2019 | 10.74M |
Date | Value |
---|---|
June 30, 2019 | 10.15M |
March 31, 2019 | 11.77M |
December 31, 2018 | 10.82M |
September 30, 2018 | 10.29M |
June 30, 2018 | 11.29M |
March 31, 2018 | 11.20M |
December 31, 2017 | 8.822M |
September 30, 2017 | 8.111M |
June 30, 2017 | 7.71M |
March 31, 2017 | 6.463M |
December 31, 2016 | 6.345M |
September 30, 2016 | 5.424M |
June 30, 2016 | 6.172M |
March 31, 2016 | 5.267M |
September 30, 2015 | 4.875M |
December 31, 2014 | 1.416M |
September 30, 2014 | 1.832M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
9.261M
Minimum
Mar 2020
20.07M
Maximum
Jun 2023
14.09M
Average
13.82M
Median
Mar 2021